If one were to begin a discussion
on the history and future of pharmacy, they would not be able to proceed very
far without addressing the prominent role pharmacy compounding has played and
will play within the industry. Woven throughout thousands of years of history,
the pharmacist was the one individual in society who carried the knowledge to
prepare drugs from vegetable, animal, and mineral sources. As the industrial
revolution evolved into the 1900’s, mass-production of drugs occurred along
with its subsequent cookie cutter, one-size for everybody mindset. But as one
could anticipate, with every action there is a reaction and thus fewer choices
of dosage forms, dosage strengths, and less individualization of prescriptions
became issues difficult to ignore. Pharmacy compounding today is now looked
upon as a major role player in health care.
One perfect example of the
unmistakable significance of compounding pharmacy includes the fact that health
care today cannot exist without it. Adding to its relevance, observers should
further note limited dosage forms and strengths are available from
manufacturers, home health care requires individualized compounded medications,
and innovative or new therapeutic approaches often are available only through
compounding.
Imprimis Pharmaceuticals, Inc.
(NASDAQ: IMMY) has a business model and strategy centered on the pulse of real
market demand for products produced through the art and science of compounding
pharmacy. One of its central strategies is the use of compounding pharmacies to
formulate proprietary compounded drug formulations and technologies and then
distribute them to physicians and patients. Vital to the compounding process,
physicians collaborate with pharmacists to reformulate FDA-approved drugs to
meet a patient’s specific medical needs. IMMY is attentive to the ideas
generated by pharmacists dealing directly with doctors and their patients to
address specific, unmet patient needs while supporting the important role and
contribution of the compounding pharmacist and compounding pharmacies in the
U.S. healthcare system.
Imprimis Ophthalmic
Anti-Inflammatory and Anti-Bacterial Combination Formulations
During the second half of 2013, the
company acquired intellectual, proprietary property related to ophthalmic compounded
formulations for intraoperative ocular injection of anti-inflammatory and
anti-bacterial agents. These formulations incorporate patent-pending
technologies which enable the combination of drugs such as triamcinolone and
moxifloxacin that do not typically distribute evenly in a suspension. IMMY
believes such formulations can potentially impact the fast-growing global
cataract surgery drug market and other markets in ophthalmology for procedures
where there is a risk of inflammation and infection. The company’s formulations
have been used as an injection, but have also been used topically as an eye
drop – both dependent on the procedure at hand. Through its use of new
technology, Imprimis solutions offer doctors alternatives to address the
primary ocular complications of ophthalmic surgery which include infection risk
and inflammation following surgery.
Imprimis Dermatology and Urology
Formulations
In addition to IMMY’s proprietary
ophthalmic formulations, the company acquired intellectual property assets in
the form of provisional patent applications related to topical formulations
comprising tranexamic acid and an antibiotic which has been prescribed for
wound healing, as well as injectable formulations comprising pentoxifylline for
treatment of fibrotic conditions. The company is currently seeking to obtain
additional supporting data with respect to these formulations as part of its
assessment process. Although compounded formulations utilizing IMMY proprietary
technology are currently available through Pharmacy Creations with a physician
prescription, the company does not expect to market these non-ophthalmic
formulations without a successful commercial assessment.
Imprimis Pharmaceuticals’ Mission
The company seeks to identify and
assess the state of our current healthcare economy and solve unmet patient
needs through the development and commercialization of proprietary sterile and
topical drug formulations that have been prescribed by a physician and have
shown promise for patients in clinical settings. Their ultimate goal is to
deliver high quality, novel, and customizable medicines to physicians and
patients affordably. As a result of the growing demand for the company’s
“Dropless” formulations and the planned launch of its “Defeat IC” and related
lido-hep compound, Imprimis is pursuing opportunities to expand its
prescription dispensing capabilities aimed at reaching nationwide distribution
for its formulations within the next six to nine months.
For more information, visit
www.imprimispharma.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
